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Abstract
Spinal cord injury (SCI) induces a series of anatomic and physiological disorders which
have severe repercussions on neural function. SCI is classified chronologically into an
acute (primary and secondary phase) and a chronic phase. The primary phase results
directly from the initial trauma and is comprised of disturbances in neural tissue (mainly
axons), blood vessels, and spinal shock. Secondary injury results from a series of time-
dependent pathophysiological changes, beginning in the first minutes after SCI and last-
ing days and weeks. This phase is characterized by biochemical and immunological
alterations in the injury site and periphery, leading to neuronal over-excitation, apoptosis,
and axonal demyelination. In chronic stages, the pathophysiology consists of disturbances
in fiber organization, oligodendrocyte apoptosis, fibroglial scar formation, and cyst for-
mation, leading to parenchymal alterations such as syringomyelia and hydromyelia hin-
dering the possibility for functional basal axonal regeneration. This chapter will review a
wide range of pharmacological and nonpharmacological therapeutic strategies in preclin-
ical and clinical phases, each targeting different pathological mechanisms of SCI in acute
and chronic stages of SCI; taking into account limitations, advances, scope, and new
trends. The chapter focuses on the general aspects of SCI pathophysiology, pharmacolog-
ical and nonpharmacological treatments acute and chronic stages of SCI.
Keywords: spinal cord injury, pharmacological strategies, nonpharmacological strategies,
therapeutic, acute and chronic
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1. Introduction
The spinal cord (SC) has three major functions in human beings: sensibility, autonomous
control, and motor control. Destructive mechanisms following SCI can have grave conse-
quences on these functions [1, 2].
Traumatic SCI can originate devastating consequences on patients and those close to them,
requiring a great number of lifestyle adjustments. This injury results most commonly from
vehicular accidents, falls, and sports injuries, among other traumatic accidents. According to
the World Health Organization (WHO), there are approximately between 250,000 and 500,000
cases of SCI per year. Among these, 90% are traumatic in nature with an increased mortality
risk within the first year [3].
The pathophysiology of SCI can be divided into primary and secondary damage based on the
self-destructive mechanisms following initial injury. These mechanisms can be further divided
into three phases according to their temporality: acute, subacute, and chronic phase. The acute
phase is characterized by ionic changes, which interrupt nerve impulses and lead to edema;
the subacute phase involves a series of events including ischemia, vasospasm, thrombosis,
inflammatory response, free radicals (FR) production, lipid peroxidation (LP), and the activa-
tion of autoimmune responses resulting in apoptosis. In the chronic phase, all the auto
destructive mechanisms generated during the acute and subacute phase increase and demye-
lination processes are triggered, alongside the formation of a glial scar, which hinders axonal
regeneration [4–6].
The objective of this chapter is to review a wide range of pharmacological and nonpharma-
cological therapeutic options, each targeting different pathological mechanisms in the different
time phases of SCI.
2. SCI pathophysiology
2.1. Acute and subacute phases
Primary damage occurs mechanically at the moment of injury, leading to irreversible sequelae.
There are three main mechanisms of injury:
a. Contusion in the SC without visible loss of its morphology producing a necrotic zone at
the impact site, which mainly affects the dorsal region of the SC.
b. Laceration or transection, which results from the penetration of the SC or extreme trauma,
and affects SC conduction depending on whether the tissue is partly or completely
transacted.
c. Compression caused by fractures in the vertebral column, which limit irrigation and can
occur without injuring the surrounding ligaments, resulting in ischemic damage in the
area where the blood flow was interrupted [3, 5, 6].
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Mechanical trauma initially tends to damage primarily gray central matter with a relative
preservation of peripheral white matter. Irreversible damage to the gray matter occurs
during the first hour after injury, with the same happening to white matter within the first
72 hours [5]. As a result of the mechanical injury, superficial vessels undergo vasospasm,
originating an intraparenchymal hemorrhage, which damages the microvasculature of the
gray matter [7]. This in turn leads to the decreased perfusion and local infarcts due to
hypoxia and ischemia, depending on the severity of the lesion. Furthermore, these can be
aggravated by neurogenic or hemorrhagic shock, arterial hypotension, bradycardia, arrhyth-
mias, and intraparenchymal hemorrhage. Therefore, the damage initiated by mechanical
trauma has a maximum extension from the third to fifth day after injury, extending from
the rostral and caudal segments to the epicenter of the lesion, and affecting both gray and
white matter. The main consequence of hemorrhage is neuronal death by necrosis, which is
observed primarily in the gray matter [7–9].
The primary lesion causes the rupture of the blood brain barrier (BBB) at the injury site,
leading to a focal destruction of neural tissue, which destabilizes neural and endothelial
membranes [10]. This phenomenon results in the death of neurons in the hours following SCI,
and is associated with edema, negatively impacting blood flow to the SC, thus extending the
inflammatory response [11]. Therefore, primary injury gives rise to the cellular and molecular
processes characteristic of the secondary injury stage, which promotes neuronal death and
alter genetic expression patterns [12].
Autodestructive mechanisms triggered after SCI can persist with time, and thus be found in
acute, subacute, or chronic phases. The acute and subacute phases are characterized by the
following mechanisms:
2.1.1. Ionic deregulation
The first secondary mechanism appearing after SCI, ionic deregulation results from an increase
intracellular Na+ and Ca2+ concentration and a decrease of K+ and Mg2+ ions. This results in the
depolarization of neuronal membranes, decreased number of ionic channels, and increased
transportation of water molecules associated with Na+ and Ca2+ ions, leading to edema [13].
2.1.2. Edema
Vasogenic edema initially appears as a consequence of the BBB rupture, and is further propa-
gated by the loss of ionic regulation, giving way to water accumulation in extracellular spaces.
Water accumulation is strongly related to the intensity of the initial trauma [14]. The presence
of edema in any part of the CNS results in the compression of adjacent tissue, which leads to
ischemia and promotes the development of other self-destructive mechanisms, such as the
release of FR, LP, and inflammation [1, 14].
2.1.3. Excessive release of intracellular calcium
Once the lesion occurs, partial or total loss of the cellular membrane in neurons and axons is
triggered, resulting in the depolarization due to the entrance of high concentrations of Ca2+ [13].
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The resulting ionic unbalance and edema contribute to the massive entry of Ca2+, which is
intrinsically related to neurotoxicity by the exaggerated release of glutamate and the activation
of proteases and phospholipases. This activation triggers the destruction of neurofilaments
and the destabilization of key proteins for cellular support, favoring axonal collapse, and
fragmentation in the first hours or days post-trauma [15]. In addition to phospholipase
activation, the increase in Ca2+ contributes to the production of pro-inflammatory molecules,
such as arachidonic acid, leukotriene, and thromboxane due to the release of fatty acids from
membrane phospholipids [4]. Likewise, intracellular mobilization of cytosolic Ca2+ generates
reactive oxygen species (ROS), energetic failure, cytoskeletal damage, and errors in protein
folding [16].
The sudden entry of intracellular Ca2+ likewise leads to the aforementioned glutamate
excitotoxicity. These mechanisms conjointly contribute to immediate cell death or the activa-
tion of calcium-dependent signaling pathways, which result in cellular death [15, 17].
2.1.4. Glutamate excitotoxicity
SCI affects the regular equilibrium of glutamate and aspartate in the CNS, leading to signifi-
cant alterations. Fifteen minutes after SCI, glutamate concentration increases to concentrations
six times higher than physiological levels [18]. This increase is due to the overstimulation of
ionotropic glutamate receptors (GluRs), provoked by the massive entry of Ca2+ and Na+. This
ion flow can induce a secondary increase of intracellular Ca2+, leading to an overstimulation of
viable neurons and neuronal death. This toxic effect, known as excitotoxicity [19], leads to
neuronal and oligodendrocytic death [18, 20].
This phenomenon is mainly evidenced in glial cells, with axonal-myelinating oligodendrocytes
showing greater susceptibility. Excitotoxicity signals are regulated by 2-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate type GluRs; their overactivation facili-
tates oligodendrocyte death and consequent demyelination after SCI [21].
2.1.5. FR production
Microvascular disruption, ionic deregulation, glutamate increase, mitochondrial dysfunction,
and the activation of inflammatory mechanisms stimulate the formation of FR [4, 6, 22]. The
cascade of FR production begins with intracellular Ca2+ elevation and the production of
uncoupled electrons, which bind to O2 molecules, transforming them into superoxide radicals
(O2
) capable of increasing oxidative damage by promoting further FR formation [23].
Damage induced by FR, denominated oxidative stress or nitrosative stress, occurs when exces-
sive amounts of ROS and reactive nitrogen species (RNS) are produced, along with low levels of
antioxidant defenses. FR production following SCI can damage cellular lipids, proteins,
deoxyribonucleic acid (DNA), and ribonucleic acid (RNA), causing mutations or irreversible
damage, which leads to cellular death [24]. Moreover, peroxidase (Prx) 1/6 and manganese
superoxide dismutase (MnSOD) are modified by phosphorylation, oxidation, or nitration during
oxidative stress after injury, inhibiting their antioxidant functions [25].
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2.1.6. Lipid peroxidation
One of the most important pathophysiological mechanisms derived from FR production is LP.
ROS such as hydroxyl radicals (OH) and O2
, combine with nitric oxide (NO) to form the
superoxidant agent peroxynitrite (ONOO). These reactants, in turn, can protonate at a physi-
ological pH level, forming peroxynitrous acid (ONOOH) [23, 26].
At a physiological pH, ONOO reacts with polyunsaturated fatty acids (PUFAs), taking one
electron to form a lipid radical (L•) that interacts with molecular oxygen to form peroxyl lipid
radicals (LOO•). Without regulatory mechanisms, LP will result in membrane depolarization
and ensuing demyelination in the SC [26, 27]. Substantial damage induced by FR involves an
oxidative attack to the cellular membrane, which is made of PUFAs (arachidonic acid, linoleic
acid, eicosapentaenoic acid, or docosahexaenoic acid) [28, 29]. Two aldehydic products arise
from LP: 4-hidroxynonenal (4-HNE) y 2-propenal (acrolein). These molecules have been char-
acterized in SCI models, forming covalent bonds with basic amino acids found in cellular
proteins, and thus altering their structure and functional properties [28].
Likewise, the inflammatory response is partially responsible for FR production after SCI due to
its stimulation of NO production. This molecule is produced by different cellular types after SCI
and is capable of damaging medullar parenchyma when produced by inducible nitric oxide
synthase (iNOS) [29]. High concentrations of NO, which are mainly produced by iNOS, require
an immunological/inflammatory stimulus, such as inflammatory cytokines (IL-6, IL-1, and IFN-γ),
resulting in nanomolar quantities produced for prolonged time periods [30, 31].
After SCI, high concentrations of NO (produced by iNOS) and peroxynitrite increase up to three
or five times, reaching their peak 12 hours after injury [32]. Some studies have detected iNOS
activity 3, 4, 24, and 72 hours following SCI, vinculating its presence to LP, and neural destruc-
tion [31–33]. High concentrations of NO simultaneously participate in cellular damage and
increase vascular permeability. Consequently, NO contributes to the formation of edema, as well
as excitotoxicity through the release of high concentrations of Ca2+ and glutamate. Furthermore,
NO alters the electron transport chain in the mitochondria, generating further FR by affecting
enzymes with a sulfuric catalytic center, such as ubiquinone succinate [34]. In addition, iNOS
expression and production of NO have a retroactive effect on the development of the inflamma-
tory response, due to their role in the production of cyclooxygenase 2 (COX)-2, which increases
the levels of inflammatory products such as prostaglandins and thromboxane [34, 35].
2.1.7. Inflammatory response
Immediately after the traumatic rupture of the BBB, an inflammatory reaction takes place. This
reaction involves the actions of chemical mediators and the participation of inflammatory cells,
derived from the activation of resident immunological cells (astrocytes and microglia) and
recruitment of peripheral cells (macrophages, lymphocytes, etc.) [8, 36].
The production and release of pro-inflammatory cytokines and chemokines are some of the
first inflammatory events triggered after SCI. Cytokines such as IL1, IL6, and tumor necrosis
factor-alpha (TNFα) are known as mediators of the peripheral inflammatory response, and are
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synthesized and released by various cells in the CNS. TNFα promotes the immediate recruit-
ment of neutrophils to the damaged site by inducing the expression of molecules, such as
endothelial cell intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion mole-
cule 1 (VCAM-1). It also stimulates the release of IL8, an important neutrophil chemotactic
factor, which modifies endothelial cells permeability and consequently affects the BBB. Fur-
thermore, TNFα also stimulates astrocyte proliferation and hypertrophy, promoting the for-
mation of a glial scar that acts as a barrier against possible regeneration [37, 38].
During the inflammatory response, the infiltration of immunological cells is the principal
contributor to neuronal degeneration. These cells are guided from the periphery to the injury
site by chemokines and cytokines released by microglia cells and astrocytes, which conjointly
with peripheral macrophages constitute the main components of the injury [10, 39]. These
events begin with the acute inflammatory response and persist in the chronic phase, charac-
terized by a constant migration of cells (neutrophils, macrophages, lymphocytes, basophils,
and eosinophils) from the periphery. This leads to the increased levels of inflammatory cyto-
kines and extended damage, as well as the increase in neural destruction, which hinder the
possibility of reparation and tissue regeneration [40, 41].
After injury, two infiltration waves have been described. The first wave, constituted by polymor-
phonuclear cells (PMN), predominates during the first few hours following injury. Neutrophils
appear in the vein and venule walls surrounding the injury within the first 4 hours and have
been observed from 8 to 24 hours post-trauma. The inflammatory response is reflected by
increased number of leukocytes in the cerebrospinal fluid (CSF), infiltration by PMN, an increase
in leukotriene levels (mainly LTB4), and myeloperoxidase activity [41]. The second infiltration is
characterized by the presence of macrophages, which are observed in the first 2 days, reaching
peak levels at day 5–7. After 2 days, proliferation and recruitment of macrophages andmicroglia
occurs, alongside leukocyte infiltration from the third to seventh day. All of these alterations and
phenomena that occur in a molecular environment promote gradual tissue degeneration,
destroying the necessary anatomic substrate for neurological recovery [40].
Macrophage and monocyte infiltration after SCI aims to remove cellular debris and stimu-
late the infiltration of new blood vessels and parenchymal cells. The infiltration of these cells
helps T-cell interaction, regulating their activation and proliferation through their role as
antigen-presenting cells (APC) [42]. The microglia are pluripotent resident cells capable of
expressing different phenotypes. The intensity of inflammatory response varies according to
lesion severity, affecting cell recruitment and the magnitude of the immune response at the
site of injury. Regulation of the inflammatory response occurs due to the interaction of the
microglia with T cells, leading to their activation against specific antigens, and thus regulat-
ing the immunological response and subsequent phases [43].
Microglia cells are distributed across the CNS, serving as pathological sensors, which react to
harmful stimuli [44]. The activated microglia migrate to the pathogen-invaded injury site and
transform from the resting phenotype (ramified cells) into amoeboid cells (phagocytic) [45].
Activated microglia can release a series of cytokines, chemokines, and enzymes, depending on
the activation stimulus, including: IL1-β, IL-6, TNFα, transformation growth factor-β1 (TGF-β1),
macrophage-colony stimulating factors (M-CSF) [46]; iNOS, neural growth factor (NGF),
neurotrophin-3 (NT-3) and brain neuronal derived factor (BNDF) [43, 47].
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Lymphocytes are cells that modulate the intensity of the inflammatory response. Their partic-
ipation following SCI has also been related to neural tissue damage due to their production of
pro-inflammatory cytokines, such as IFNγ and IL1β [43, 48]. IFNγ is directly related to
neuronal destruction, inducing the expression of further pro-inflammatory cytokines (TNFα,
IL6, IL12, and IL1β) and pro-inflammatory molecules (ROS and iNOs) through induction of
nuclear factor kappa B (NFkB) and activator protein-1 (AP-1) signaling pathways [11, 43, 49].
After SCI, a self-reactive/autoreactive response, defined as an immune response against autolo-
gous constituents, is triggered within the CNS [50–52]. This response targets neural constituents,
such as myelin basic protein (MBP), promoting an increase in the expansion of neurological
damage at the injury site. This response is capable of increasing the damage to the nerve tissue,
but is also able to promote protection and even restoration of damaged tissue [48, 52–55].
2.2. Chronic phase
In chronic stages of SCI, the formation of a barrier occurs, precluding axonal regeneration in
the area surrounding the lesion. This barrier consists of two main components: glial (astro-
cytes) and fibrotic elements that synthesize inhibitory molecules, hindering interconnection
and axonal regeneration [56]. It has been observed that the cicatrization process restores the
vital function of the blood–brain-barrier and limits the resulting damage at the injury site.
However, in addition to having beneficial effects, this process also prevents restoration [57].
During this phase, some disturbances regarding the organization of fibers are observed, such as
demyelination, Wallerian degeneration, oligodendrocyte apoptosis, and the formation of a scar
of collagen fibers [56, 58, 59]. In this phase, a strong, nonregulated interaction between the CNS
and the immune system takes place, which includes the vegetative innervations to the lymphatic
and endocrine tissue that aggravate the degeneration process of major functions [57].
The glial scar around the injury is formed by a wide net of fibrous astrocytes and collagen
fibers, which release proteoglycans and neurofilaments, such as vimentin and nestin, which act
as inhibitory molecules of neural growth [59, 60]. Therefore, the fibrous scar developed after an
injury in the CNS is considered a hindrance for axonal regeneration [59]. Although tradition-
ally astrocytes have been considered to be detrimental to regeneration, they possess beneficial
effects when presented in their reactive form at the glial scar, including BBB repair and
modulation of the immune response [61].
Astrocytes present a gradual response to the lesion, including changes in gene expression,
hypertrophy, extension of the process, and in some cases cellular division [62, 63]. The cur-
rently known factors responsible for increasing the formation of glial scars in SCI are
transforming growth factor β (TGF-β) [64] and INF-γ, among others [62].
Reactive astrogliosis, defined as an atypical increase of astrocytes, is characteristic of astrocytes
surrounding the lesion. This phenomenon presents with a rapid synthesis of intermediate
filaments, such as glial fibrillary acidic protein (GFAP), vimentin and nestin. Moreover, there
is an excessive secretion of extracellular matrix (ECM) components, such as tenascins, type IV
collagen, and chondroitin sulphate proteoglycans (CSPGs), which form a glial scar at the
injury site. This scar develops into a fibrous barrier, preventing regeneration of nervous
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connections adjacent to the lesion. Furthermore, the reactive astrocytes contribute to the
release of pro-inflammatory cytokines, such as TNF-α, INF-γ, IL-1β, and IL-6, which inhibit
differentiation processes of neural stem cells (NSC) [65], and contribute to the chronic inflam-
matory response [62].
In addition, the formation of a glial scar favors cavitation, a process detrimental to regenera-
tion at the injury site. This phenomenon can lead to the extension of the injury size days or
even weeks after the lesion, resulting in the formation of an encapsulated scar, which prevents
neuronal connection [66, 67].
At the chronic stage, the central canal is frequently involved in fluid-filled cyst development,
which gives rise to malformations in the SC parenchyma; this condition is known as syringo-
myelia [68]. This term, first introduced by Ollivier D’Angers in 1827, derives from the Greek
word for tube (syrinx) and is used to describe dilation of the central canal extending over many
segments. Before trauma, CSF normally flows into the inner parts of the brain and SC. How-
ever, SCI evokes morphological changes, which disrupt correct circulation enhancing the
volumetric growth of cavities. Syringomyelia appears to be related to irregular pressure con-
ditions and hydrodynamic mechanisms related to the CSF [68, 69].
Hydromyelia, a closely related term that is often used interchangeably, also refers to a dilatation
of the central canal by CSF. Some have defined hydromyelia as a congenital dilatation [70] of the
central canal, which is partially lined with ependymal cells, strongly associated with hydroceph-
alus, an obstruction of the foramina of Luschka and Magendie [71]. The term syringomyelia has
been affixed to every kind of intramedullary cyst, with some authors defining it as a cavity
distinct from the central canal and lined by ependymal cells or primarily glial cells [71, 72].
However, others restrict its use to certain subtypes of cystic lesions and distinguish syringomy-
elia, hydromyelia, or myelomalacia as separate entities. In spite of this, some authors combine
these terms into syringohydromyelia or hydrosyringomyelia [71]. Lee et al. stated that a clear
communication between intramedullary cavities and the ventricular system is rarely demon-
strated, making it difficult to differentiate syringomyelia from hydromyelia, although a truly
eccentric location within the spinal cord may be more characteristic of syringomyelia than of
hydromyelia [73]. Batzdorf states that the distinction between syringomyelia and hydromyelia is
no longer considered absolute or critical [72].
3. Therapy after acute SCI
In recent years, neuroprotective or neuroregenerative strategies regarding the injury site have
been chosen to mitigate autodestructive events following a SCI. These strategies include:
preservation or regeneration of damaged neural tissue, neutralization of toxic mediators, and
increasing tissue resistance to toxicity [74].
Although there is a substantial evidence showing new preclinical strategies that aim to pro-
mote neuroprotection, achieved with certain efficiency in murine SCI models [75], there are
few clinically approved treatments available to patients with SCI. Currently, clinical treatments
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are limited to surgical decompression, blood pressure control, and the possible use of methyl-
prednisolone (MP), which is not recommended due to its secondary effects [76].
However, for each treatment strategy, it is important to consider the time elapsed between the
injury and the initial treatments, in order to promote a beneficial effect by inhibiting or diminishing
secondary damage as rapidly as possible. Despite the promising results shown by several treat-
ments, there is currently no therapy that satisfies all the requirements necessary for an optimal
recovery [77].
3.1. Pharmacological therapies
During the last 25 years, different preclinical and clinical studies evaluating neuroprotection in
SCI have been conducted. As previously mentioned, careful consideration of the time frame
for treatment after SCI is essential when selecting a therapeutic option. At the clinical level,
conventional norms have recommended initiating treatment within the first 3 hours following
injury. However, some preclinical studies have begun treatment administration within the first
hour after lesion, which complicates the clinical application of these therapies [75]. Diverse
drugs have been used in preclinical and clinical studies, with each having different effects
depending of the therapeutic objective. However, the majority of drugs studied as possible
neuroprotective agents focus solely on one type of damage, with some being tailored to
specific mechanisms of the primary injury. The vast majority of these have consisted of phar-
macological treatments, although many preclinical studies have included additional therapeu-
tic strategies for acute and chronic SCI. Current pharmacological agents used in the treatment
of acute SCI can be grouped into: ionic channel blockers, inhibitors of N-Methyl-D-asparate
acid (NMDA), and AMPA-kainate receptors, inhibitors of FR and LP, antiapoptotics, and
immunosupressors or immunomodulators [77]. All the therapies and their therapeutic objec-
tives are mentioned in Table 1.
Therapy Mechanism of
neuroprotection
↑ Increase
↓ Decrease
() Blocked
(+) Activated
Treatment outcome References
Preclinical therapies
Ionic channel blockers
Sodium
a) Tetrodotoxin
b) Riluzole
() Sodium entry channels after
SCI
Binds to voltage-dependent sodium channels in
nervous system cell membranes, facilitating
motor function recovery by reducing long-term
white matter loss, thus improving neural tissue
preservation.
Increases the survival and reinnervating capacity
of injured motor neurons; conferred significant
neuroprotection and behavioral recovery, sparing
both gray and white matter.
[78, 79]
[80, 81]
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Therapy Mechanism of
neuroprotection
↑ Increase
↓ Decrease
() Blocked
(+) Activated
Treatment outcome References
Calcium
a) Nimodipine ↓Oxidative damage caused by
FR
Decreases LP end products, such as MDA and
4-Hydroxy Acrolein, resulting in a better motor
recovery. However, it should be noted that
nimodipine does not allow membrane repair.
[82, 83]
Inhibitors of NMDA and AMPA-kainate receptors
a) Memantine
b) Gacyclidine
c) NBQX
↓ Neurological damage by
glutamate and NMDA.
()noncompetitive NMDA
receptor
AMPA-kainate receptor
antagonist.
Noncompetitive NMDA antagonist that prevents
neurotoxicity. In combination with antiapoptotic
agents, provides better histological and clinical
results, diminished necrosis and apoptosis.
Improved motor recovery, neural tissue
preservation in a dose–dependent manner. In rats,
gacyclidine exerts dose- and time-dependent
neuroprotection.
Improves mitochondrial function and reduces
levels of ROS and lipid peroxidation products.
[84, 85]
[86, 87]
[88]
Inhibitors of FR and LP
a) PUFAs
b) Glutathione (GSH)
↓FR formation, scavenging of
ROS and RNS.
() FR by the free thiol group.
Prevents white matter damage, increases synaptic
connections, neuronal survival, and improves
motor recovery. Possesses antioxidant and anti-
inflammatory effects.
Anti-excitotoxic peptide through the inhibition of
the union between specific ligands and inotropic
GluRs by the modulation of redox reactions.
Improves motor recovery, rubrospinal tract
neuronal survival, blood flow stabilization.
[89–96]
[97–100]
Antiapoptotics
a) zDEVD-fmk
b) LEHD-fmk
() Caspase 3 and 9
respectively
The application of z-DEVD-fmk reduces secondary
tissue injury and helps preserve motor function.
Electron microscopy showed that z-LEHD-fmk
treatment protects neurons, glia, myelin, axons,
and intracellular organelles.
[101, 102]
Immunosuppressive or immunomodulatory drugs
1. Inhibitors of cyclooxygenase
a) Indomethacin
b) Celecoxib
c) Meloxicam
() COX 1 and COX 2
() COX 2
() COX 2
Mixed results: some report improved
neurological function and blood flow to injury
site, as well as decreased neuronal damage, while
others report delayed recovery.
Reduction of prostanoids and FR synthesis,
inhibition of arachidonic acid pathways.
Increased motor recovery and diminished
damaged spinal tissue.
Improved neurological function, amelioration of LP.
[103, 104]
[103]
[105]
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Therapy Mechanism of
neuroprotection
↑ Increase
↓ Decrease
() Blocked
(+) Activated
Treatment outcome References
2. Immunophilin ligands
a) Cyclosporine A
b) Tacrolimus
() Calcineurin activity Inhibits the proliferation of T-helper lymphocytes
and interferes with cytokine production (IL-1, IL-
2 e IL-6), cytoskeleton motility of neutrophils, and
activation of iNOS or ROS production.
Reduces LP levels, glutamate excitotoxicity, and
demyelination processes, increasing neuronal
survival and motor recovery.
NF-kB and caspase 3 inhibition, leading to
improved recovery and reduced neuronal loss.
In mesenchymal stem cells (MSCs)
transplantation, improves MSCs survival and
neurological recovery after SCI.
Tacrolimus may induce neuroregeneration by
binding to heat shock protein 90.
[104, 106–
109]
[110–114]
3. Immunomodulatory peptides
a) Monocyte
locomotion inhibitory
factor (MLIF)
b) Nogo-A
c) A91
↓ VCAM-1, pro-inflammatory
cytokines (IL-1β, IL-6, IL-12,
and IFN-γ)
(+) T-cell-mediated protective
autoimmunity
(+)T-cell-mediated protective
autoimmunity
Motor recovery and survival of ventral and
corticospinal tract neurons associated with a
reduction in iNOS gene expression and up
regulation of IL-10 and TGF-β expression. MLIF
also reduces the concentration of nitric oxide and
the levels of lipid peroxidation in systemic
circulation.
Nogo-A-derived peptide p472 and the transfer of
anti-Nogo-A T-cells showed a significant
reduction in neuronal loss.
Promotes motor recovery and the long-term
production of BDNF and NT-3.
Reduces LP levels, iNOS expression, NO levels,
caspase 3 activity, and TNF-α concentration.
A91 combined with GME induced a better motor
recovery, a higher number of myelinated axons, and
better rubrospinal neuron survival than A91 alone.
[115, 116]
[117, 118]
[100, 119–
125]
Clinical therapies
Methylprednisolone () Immune response Contradicting data, with some showing
improved motor recovery and others showing no
recovery and increased side effects.
[126–128]
Minocycline Multiple anti-inflammatory
pathways
Improved motor recovery and decreased cell
death through inhibition of caspase 3, matrix
metalloproteinases, NO levels, and TNF-α.
[129–131]
GM-1 Ganglioside ↓ Excitatory neurotoxicity Improved motor recovery evaluated by American
Spinal Injury Association (ASIA) motor, light
touch, and pinprick scores.
[132–134]
Table 1. Pharmacological treatments used in acute SCI.
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3.2. Nonpharmacological therapies
Nonpharmacological interventions are frequently advocated, although the benefit and harm
profiles of these treatments are not well established. This may be due in part because of
methodological weaknesses in available studies. However, preclinical studies have demon-
strated neuroprotective effect, although results from clinical studies remain controversial and
require further studies. These treatments are summarized in Table 2.
Therapy Mechanism of neuroprotection
↑ Increase
↓ Decrease
() Blocked
(+) Activated
Treatment outcome References
Preclinical therapies
Vitamins
a) Vitamin B3
(niacin)
b) Vitamin C
(ascorbic acid)
c) Vitamin E (alpha-
tocopherol)
Phenotypic shift in macrophages
from M1 to M2
() FR formation
() FR formation
Reduced p65 NF-κB phosphorylation,
reducing M1 markers such as iCD86, IL-12,
and IL-6 and increasing anti-inflammatory
M2markers, such as CD206, IL-10, and IL-13.
Reduces tissue damage and improves
functional recovery in rats.
Improves cell survival and motor function
significantly following SCI.
[135]
[136, 137]
[137, 138]
Resveratrol ↑ Transcription factor Nrf-2 and
sirtuin (SIRT) 1
Reduces neutrophil infiltration, production
of inflammatory cytokines (IL-1β, IL-10,
TNF-α), and myeloperoxidase (MPO) by
inhibition of NF-κB; diminishes iNOS
expression, apoptosis, and caspase-3, as well
as inducing important locomotor recovery.
[139–142]
Gene therapy
Chondroitinase
gene therapy via
lentiviral vector
(LV-ChABC)
() Chondroitin sulfate
proteoglycans (CSPGs)
Reduced cavitation and enhanced
preservation of spinal neurons and axons.
Improved sensorimotor function and
increased neuronal survival correlated with
reduced apoptosis.
[143]
Hypothermia Vasoconstriction,
() Inflammatory response
Decreases the degree of the hemorrhage at
the injured site and neurotoxicity by
reducing the levels of glutamate and
glutamanergic receptors.
Prevents changes in the BBB, thus hindering
extravasation of leukocytes into the CNS.
Inactivation of production of pro-
inflammatory cytokines, such as IL-1β, IL-18,
and TNF-α. Also reduces O2
, NO, and OH
FR. Reduces cell death and apoptotic
mechanisms through caspase-3 and
cytochrome C inhibition.
[144, 145]
Cell therapy
a) Schwann cells (+) Myelination Treatment with these cells improves sensitive
and motor functions due to the
[146, 147]
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Therapy Mechanism of neuroprotection
↑ Increase
↓ Decrease
() Blocked
(+) Activated
Treatment outcome References
b) Embryonic stem
cells.
c) Olfactory
ensheathing cells
(OECs)
d) MSCs
Pluripotent cells capable of
differentiating into every type of cell
Found in the center and periphery of
the olfactory nerve; capable of
differentiating into neuronal or glial
lineage cells
Obtained from bone marrow; capable
of differentiating into every type of
cell
remyelinating potential of Schwann cells,
permitting the transmission of action
potentials through regenerated axons
wrapped in Schwann cells.
Induce motor recovery through the ability to
transform into astrocytes, oligodendrocytes,
and/or neurons in vitro prior to
transplantation, in order to avoid their
tumorigenicity.
Enhanced locomotor recovery, axon
myelination, and neuroprotection.
MSCs may facilitate recovery from SCI by
remyelinating spared white matter tracts
and/or enhancing axonal growth with low
immunogenicity. Modulate the
inflammatory microenvironment to reduce
pro-inflammatory cytokine levels.
[148]
[149]
[150, 151]
Low-energy
extracorporeal
shockwave therapy
(ESWT)
↑ Electric stimulus Improved motor and sensory recovery,
decreased neural cell death. Stimulates
angiogenesis and neurogenesis.
[152]
Physical therapy ↓ Spasticity
↑Neurological outcome
Upregulates the expression of NT3, NT4,
BDNF, and GDNF, while reducing levels of
apoptosis-related proteins such as caspase 3
and 9.
Induces axonal regeneration, broadening the
scope of physical therapy from
neuroprotection to neuroregeneration.
[152–156]
Clinical therapies
Cell therapy
Autologous
transplant of MSC
Obtained from bone marrow; capable
of differentiating into every type of
cell
Improved motor, sensory recovery, and
neurological outcome.
Improved sexual function and bladder and
bowel control
Increased levels of BDNF, NGF, NT3, and
NT4.
[157–161]
Physical therapy ↓ Spasticity
↑Neurological outcome
Further translational studies are required in
order to provide favorable results in patients
similar to those seen in animal models of SCI.
However, patients with incomplete SCI saw
an improvement on their ASIA score after
receiving physical therapy.
[162–164]
Table 2. Nonpharmacological therapies used in acute SCI.
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4. Therapies for chronic SCI
Many patients with chronic SCI experience little partial recovery with the use of acute phase
treatments. When compared to acute SCI treatments, the efficacy of therapies that promote
axonal regeneration in chronic models is reduced due to the generalized stability, induced by
protective means or restoration promoters not present during the acute phase [165]. Studies
indicate that this period of stability is reached in up to 3 months [166], followed by a progres-
sive decline of neurologic functions in rodents that underwent SCI [167, 168].
Treatments for chronic SCI focus on avoiding or improving characteristic pathophysiological
mechanisms, such as glial scar formation, demyelination, and astrogliosis. Moreover, it must
be emphasized that while strategies for acute SCI are limited to preventing further damage,
therapeutic strategies for chronic SCI instead focus on promoting neuronal regeneration and
treating accompanying symptoms of chronic complications. Pharmacological and nonpharma-
cological therapies utilized in the treatment of chronic SCI are summarized in Tables 3 and 4.
Therapy Mechanism of
neuroprotection
↑ Increase
↓ Decrease
() Blocked
(+) Activated
Treatment outcome References
Preclinical therapies
Antagonists of Rho signaling pathway
a) C3 transferase
b) Y27632
c) Fasudil
d) P21
e) Ibuprofen
()Rho protein
()Rho protein,
nonselective inhibitor
()Rho protein
()Rho protein
Stimulates axonal growth and improves motor function.
Promotes axonal regeneration and motor function recovery.
Conjoint administration with MP promotes recovery of motor
activity and reflex movements, as well as tissue preservation.
Capable of stimulating axonal regeneration and improving
motor function of extremities.
Enhances recovery by limiting tissue loss and stimulating axonal
growth.
[165]
[166]
[167]
[168]
[169]
Glial scar inhibitors
a) 2,20-bipiridine
(BPY).
b) Decorine
c) Olomoucine
d) α,α’-dipyridyl
() prolyl 4-
hydroxylase
() TGF-β
() CDK1/Cycline B
and related kinases
() prolyl-4
hydroxylase
Growth of corticospinal tract neurons through the injury site and
improved motor function recovery.
Suppresses glial scar formation, favors axonal growth.
Limits astroglial proliferation and increases GAP-43 expression,
improving motor function.
Decreases collagen synthesis.
[170]
[171]
[172]
[173]
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Preclinical therapies
Glial scar removal ↓ or () glial scar (Surgical) Promotes axonal development, although
surgical removal may lead to a second
injury.
[180]
Biocompatible matrices
a) Fibrin glue (Tissucol)
b) Alginate
c) Hyaluronic acid
Fibrinogen and thrombin compound,
potentially adequate biological vehicle
for cell transplant.
Vehicle for drug release, cellular
encapsulation and cellular transplant
Porous structures that gradually release
growth factors, cellular encapsulation,
or drugs
Promotes growth and incorporation of
primary myelinated and unmyelinated
afferent axons, and intervenes in the
support and directionality of axons with
Schwann cells.
Fibrin-stabilizing factor (Factor XII), also
contained in Tissucol, favors migration of
MSCs on the highly reticulated structure
of the glue and increases their
proliferation.
Facilitates axonal guidance and cell
adherence by delivering ECM
components, such as fibronectin, laminin,
collagen, and polyornithine, alongside
progenitor neuronal cells.
Minimizes the formation of glial scar and
promotes astrocyte and microglia
migration.
[181,
182]
[183]
[184]
Therapy Mechanism of
neuroprotection
↑ Increase
↓ Decrease
() Blocked
(+) Activated
Treatment outcome References
e) ChABC () ECM molecules Promotes spinal cord plasticity along injured corticospinal tract
and uninjured serotonergic projections, facilitates growth of new
fibers, and stimulates rubrospinal projection neuron growth.
[174, 175]
Anti-Nogo therapies
a) Nogo receptor
(NgR)
Myelin-associated
inhibitors
NgR immunization markedly reduced the total lesion volume,
improved locomotor recovery and grid walking performance.
[176]
Clinical therapies
Rho-ROCK
inhibitor
Cethrin/VX-210
()Rho protein Significant improvement in long-term motor scores (18.5 ASIA
points) for cervical patients. Currently under study in a phase III
trial in patients with acute cervical SCI which commenced in
2016.
[177, 178]
Anti-Nogo
antibodies
Myelin-associated
inhibitors
Promotes axonal sprouting and functional recovery. [117, 179]
Table 3. Pharmacological therapies in chronic SCI.
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Preclinical therapies
d) Polyethylene glycol
e) Matrigel
Seals injured membranes and allows
them to reassemble
Matrix conformed by multiple growth
factors and extracellular proteins
Repairs cell membranes in the CNS,
although it does not provide three-
dimensional support.
Compounds facilitate cellular adherence,
differentiation, Schwann cell growth, and
axonal regeneration.
[185]
[186]
Cell therapies
a)Neural stem cells
b) Mesenchymal stem
cells
c) Schwann cells
d) OECs
Integrates with host circuits to enhance
behavioral recovery
Modulate inflammatory response,
promote angiogenesis
Stimulation of remyelination
Phagocytosis of debris and microbes,
growth factor signaling
Improves phrenic motor output after high
cervical SCI, improving spontaneous
respiratory motor recovery.
Promotes repair by anti-inflammatory
molecule secretion and stimulation of
macrophage polarization, secretion of
trophic and neurotrophic factors.
Promotes angiogenesis, prevents
apoptosis, and stabilizes the BSB through
astrocyte regulation, forming axonal
guidance filaments through the injury site.
Increased preservation of white matter
and host Schwann cells and astrocyte
ingress, as well as axon ingrowth and
myelination.
Improves neurite outgrowth and
endogenous remyelination, as well as
white matter preservation, sensory, and
motor recovery.
[187,
188]
[189–
195]
[196,
197,
201]
[198–
200,
202–
204]
Combination therapy
a) Cocktail with 10
growth factors.
b) Anti-Nogo-A antibody
followed by ChABC and
physical rehabilitation.
c) ChABC and NSCs
d) A91 and surgical glial
scar removal.
↑ NT-3, BDNF, EGF, βfgf, GDNF, PDGF,
αfgf, HGF, IGF-1, and calpain inhibitor
in a fibrin gel conjointly with NSC
transplantation
Myelin-associated inhibitors
() ECM molecules
↓ spasticity
() ECM molecules
Integrate with host circuits to enhance
behavioral recovery
↑ Growth factor
() glial scar
Induces significant motor recovery.
Spontaneous recovery of forelimb
functions reflected the extent of the lesion
on the ipsilateral side and improved
motor recovery when compared to the
groups receiving individual treatments.
Histological results showed increased
neuronal regeneration.
Allows the transplanted cells to
differentiate into neuroglial cells and
permits proper axonal regeneration and
growth across the injury site, leading to
significant motor recovery.
Increases motor function.
Facilitates the axonal regeneration in the
region caudal to the injury site.
[205]
[206,
207]
[208]
[122]
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Preclinical therapies
e) Degenerated peripheral
nerves with MSCs and
fibrin glue
↑ Growth factor
(+) neural regeneration
Induces axonal regeneration and
myelination with molecules associated to
GAP-43 and neuritin, which are present in
axonal growth cones and axonal
remyelinization.
[209]
Clinical therapies
Physical therapy ↓ Spasticity Upregulation of BDNF, IGF-1, other
growth factors.
Improves axonal plasticity and
regeneration, motor function.
[210–
215]
Muscle electrical
stimulation
↑ Muscle electric stimulus Improvement in their motor and sensory
function, as well as an increase in muscle
size and strength
[216]
Spinal cord stimulation ↑ Spinal cord electric stimulus Treated patients were able to initiating
limb movement and improve posture
control, bladder emptying (urinary
retention), and sexual function. This
therapy also provoked escalated
extension-flexion movements.
Additional trials (NCT02592668,
NCT02313194) are now ongoing to assess
safety/feasibility and validate this exciting
finding, with results expected by 2018.
[217]
Glial scar removal with
NeuroRegen scaffold.
↑ Spinal cord regeneration Better recovery of autonomous nervous
functions, as well as the recovery of
somatosensory-evoked potentials of lower
limbs.
[218]
Cell therapies
a) NSC transplant
b) Oligodendrocyte
precursor cells
c) MSCs transplant
d) Schwann cells
transplant
Cervical transplant (n = 31; NCT02163876)
and thoracic transplant (n = 12;
NCT01321333). Preliminary results from
these trials do not show increased
complication rates, although results on
motor and sensitive recovery remain
pending.
Asterias Biotherapeutics Inc. phase I/II
dose-escalation trial (n = 35;
NCT02302157).
This study is expected to be completed in
2018.
Phase II/III clinical trial in South Korea
(NCT01676441) by Pharmicell Co. with
intraparenchymal and intrathecal
administration of MSC. Results are still
pending, with an estimated completion
date of 2020.
An open-label phase I trial (n = 10) by the
Miami Project to Cure Paralysis is now
[219,
220]
[220]
[220–
222]
[220]
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5. Conclusion
In conclusion, despite promising innovative advances in preclinical treatments, there is cur-
rently no consolidated therapeutic strategy at clinical settings. Further research is needed to
establish novel therapeutic strategies, including immunomodulatory strategies and combina-
torial therapy, in order to improve recovery and therefore the quality of life for patients.
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